Q: I was interested in Jeff's follow-up comment on Excelon sales declining. Who sold it before Knight in Latam and Canada? Perhaps the reason the company made a deal with Knight is to improve visibility and awareness while giving Knight's sales force new avenues for it's other products.
The price tag does not appear to be a bargain (Knight paid $360M or double for $250M sales in Biotoscan). Surely Goodman sees value in this deal. If there was no effort before then potential must be factored in and I suspect Latam is the more coveted marketplace. Can you comment and provide any previous history with sales of this product. Alzheimers us unfortunately, not going anywhere soon.
The price tag does not appear to be a bargain (Knight paid $360M or double for $250M sales in Biotoscan). Surely Goodman sees value in this deal. If there was no effort before then potential must be factored in and I suspect Latam is the more coveted marketplace. Can you comment and provide any previous history with sales of this product. Alzheimers us unfortunately, not going anywhere soon.